ACAP1 and melanoma: Overall, these results suggest that low ACAP1 levels are associated with a decreased response rate and worse clinical outcomes in ICT-treated patients, highlighting the potential clinical significance of ACAP1 for identifying patients who will benefit from ICT across multiple cancer types, especially for melanoma and lung cancer patients.